NCT01869478View on ClinicalTrials.gov

Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
StrokeIschemic Stroke
Interventions
DRUG

Intravenous Thrombolysis

DEVICE

Endovascular Arterial Reperfusion

Trial Locations (1)

32224

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT01869478 - Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke | Biotech Hunter | Biotech Hunter